Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Harmony Biosciences (HRMY) Misses Q3 EPS by 9c, Revenues Beat
November 12, 2020 8:03 AM ESTHarmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $45.6 million versus the consensus estimate of $40.07 million.
Third Quarter 2020 Financial Highlights:
Net product revenue was $45.6 million for the third quarter ended September 30, 2020.Research and development expenses were $4.2 million for the third quarter of 2020 compared with $4.3 million for the third quarter of 2019.Sales and marketing expenses were $12.6 million for the third quarter of 2020 compared with $12.9 million for the third... More